Loading…
Loading…
Announcements from Anixa Biosciences, published the moment they cross the wire. Get them by email.
2020
Dec 01, 2020
9:00 AM EST
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that it has entered into a license agreement with Cleveland Clinic for exclusive, world-wide rights to an innovative ovarian cancer vaccine technology.
Nov 23, 2020
8:30 AM EST
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that an IND (Investigational New Drug) application for its prophylactic breast cancer vaccine has been filed with the U.S. Food and Drug Administration.
Oct 27, 2020
8:00 AM EDT
It will hold a conference call on November 2, 2020 at 1:30 p.m. Pacific / 4:30 p.m. Eastern.
Sep 08, 2020
8:00 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar , Anixa's Chief Executive Officer, will present at the virtual 2020 H.C.
Jul 28, 2020
9:00 AM EDT
Its prophylactic breast cancer vaccine is making progress towards clinical trials.
Jul 20, 2020
9:00 AM EDT
Due to public health and safety concerns related to the ongoing COVID-19 global pandemic and to support the health and well-being of its stockholders, employees and others, the Company is changing its 2020 Annual Meeting of Stockholders (the "Annual Meeting") to a virtual-only format that will be held via live audio…
Jul 10, 2020
7:00 AM EDT
The European Patent Office has issued an Intention to Grant notice for the first European patent covering Anixa's novel CAR-T cancer treatment technology, which has been licensed from The Wistar Institute and is being developed at the Moffitt Cancer Center.
Jun 01, 2020
8:30 AM EDT
The Company, together with partner OntoChem GmbH, has synthesized four potential Covid-19 compounds that will advance to biological assay testing. Anixa and OntoChem announced their partnership on April 20, 2020 ( https://ir.anixa.com/press-releases/detail/947/ ) and announced discovery of its first potential Covid-19…
May 04, 2020
6:45 AM EDT
It, with partner OntoChem GmbH, has identified its first therapeutic candidate against Covid-19, and has advanced the compound into biological testing.
Apr 23, 2020
7:00 AM EDT
The publication of a peer-reviewed journal article in Biomarker Insights. The article, entitled "Detecting Prostate Cancer Using Pattern Recognition Neural Networks with Flow Cytometry-Based Immunophenotyping in At-Risk Men," supports the use of Anixa's Cchek™ early cancer detection technology as a tool to improve…
Apr 20, 2020
6:30 AM EDT
It has entered into a strategic collaboration with OntoChem GmbH to discover and develop anti-viral drug candidates for COVID-19.
Mar 02, 2020
7:00 AM EST
Data related to Anixa's recently launched Cchek™ Prostate Cancer Confirmation test (Cchek™ PCC) will be presented at the "AI and Big Data in Cancer: From Innovation to Impact" conference. Cchek™ is Anixa's artificial intelligence (AI) driven cancer detection technology.
Feb 12, 2020
7:00 AM EST
The research team lead by Dr. Jose Conejo-Garcia , Chair of the Department of Immunology at Moffitt Cancer Center, Anixa's development partner, has completed and validated the reformulation of the viral vector necessary for its CAR-T program.
Jan 06, 2020
7:00 AM EST
Data from studies utilizing Cchek™, the company's artificial intelligence (AI) driven cancer detection technology, will be presented at the American Association for Cancer Research (AACR) Special Conference on Advances in Liquid Biopsies.
2019
Dec 23, 2019
7:00 AM EST
Its chief executive officer, Dr. Amit Kumar , will present at the Biotech Showcase 2020 conference being held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco, California .
Dec 16, 2019
6:45 AM EST
The commercial launch of its Cchek™ Prostate Cancer Confirmation test (Cchek™ PCC), the first test developed with the Cchek™ artificial intelligence driven, flow cytometry based, liquid biopsy technology platform.
Dec 13, 2019
5:45 PM EST
It will hold a conference call on December 17, 2019 at 1:30 p.m. Pacific / 4:30 p.m. Eastern to discuss the progress made and the future plans for its Cchek TM artificial intelligence based cancer diagnostic test and its CAR-T based ovarian cancer therapeutic and breast cancer vaccine programs.
Dec 13, 2019
6:45 AM EST
An update regarding the chimeric antigen receptor T-cell (CAR-T) technology it is developing with its partner, Moffitt Cancer Center.
Dec 02, 2019
7:00 AM EST
Data from its ongoing studies utilizing Cchek™, its artificial intelligence (AI) driven early cancer detection technology will be presented during a poster session at the San Antonio Breast Cancer Symposium (SABCS).
Nov 26, 2019
7:00 AM EST
The addition of Genesis Research, LLC to the ongoing Cchek™ prostate cancer detection study.